GLFD Guilford Pharmaceuticals (MM)

Guilford Files Shelf Registration Statement BALTIMORE, May 20 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission. When the registration statement becomes effective, it will permit Guilford, from time to time, to offer and sell common stock, debt securities, warrants, and preferred stock, in any combination, up to a total value of $100 million. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. About Guilford Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) and AGGRASTAT(R) Injection (tirofiban hydrochloride). Additional information about GLIADEL and AGGRASTAT, including safety information, may be found at http://www.guilfordpharm.com/ / Products / Marketed Products / GLIADEL, or at http://www.aggrastat.com/. Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post- prostatectomy erectile dysfunction. CONTACT: Stacey Jurchison, Director, Corporate Communications, Guilford Pharmaceuticals, (410) 631-5022; . http://www.guilfordpharm.com/. DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Director, Corporate Communications, Guilford Pharmaceuticals, +1-410-631-5022, Web site: http://www.aggrastat.com/ Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright